A cannabinoid-centric American biotechnology company is entering the next phase of a trial focusing on improving the quality of life for cancer patients. Naples, Florida-based Enveric Biosciences has received approval from the Israeli Ministry of Health to begin Phase ½ of its triple combination cannabidiol (CBD) treatment for glioblastoma (GBM). Glioblastoma and the Brain The most common malignant brain tumor, GBM is a quick-spreading and aggressive type that starts in the brain and invades nearby tissue. GBM risk factors include prior therapeutic radiation, hereditary cancer syndromes like Lynch syndrome, decreased susceptibility to allergy, and impaired immune response. Left untreated, GBM … Continue reading Enveric Enters Next Phase Of CBD Cancer Treatment Trial